

Santosh L Saraf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6503466/publications.pdf>

Version: 2024-02-01

152
papers

2,068
citations

304701

22
h-index

289230

40
g-index

153
all docs

153
docs citations

153
times ranked

2734
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Update on Meningiomas. <i>Oncologist</i> , 2011, 16, 1604-1613. | 3.7 | 151 |
| 2 | Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 441-448. | 2.0 | 111 |
| 3 | Differences in the clinical and genotypic presentation of sickle cell disease around the world. <i>Paediatric Respiratory Reviews</i> , 2014, 15, 4-12. | 1.8 | 97 |
| 4 | Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. <i>British Journal of Haematology</i> , 2014, 164, 729-739. | 2.5 | 91 |
| 5 | COVID-19 infection in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2020, 189, 851-852. | 2.5 | 90 |
| 6 | Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 207-215. | 4.5 | 75 |
| 7 | Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service. <i>Pharmacotherapy</i> , 2013, 33, 1156-1164. | 2.6 | 70 |
| 8 | Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. <i>Leukemia and Lymphoma</i> , 2013, 54, 1989-1995. | 1.3 | 65 |
| 9 | Clinical effectiveness of decitabine in severe sickle cell disease. <i>British Journal of Haematology</i> , 2008, 141, 126-129. | 2.5 | 64 |
| 10 | Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. <i>Haematologica</i> , 2015, 100, 1275-1284. | 3.5 | 60 |
| 11 | Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. <i>Seminars in Hematology</i> , 2018, 55, 87-93. | 3.4 | 51 |
| 12 | Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1759-1765. | 2.0 | 50 |
| 13 | APOL1, α -thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. <i>Haematologica</i> , 2017, 102, e1-e6. | 3.5 | 47 |
| 14 | Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 511-520. | 1.9 | 45 |
| 15 | Nonmyeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. <i>British Journal of Haematology</i> , 2021, 192, 761-768. | 2.5 | 41 |
| 16 | Combination of Linear Accelerator-Based Intensity-Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2034-2041. | 2.0 | 40 |
| 17 | Characterization of opioid use in sickle cell disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 479-486. | 1.9 | 37 |
| 18 | Losartan for the nephropathy of sickle cell anemia: A phase 2, multicenter trial. <i>American Journal of Hematology</i> , 2017, 92, E520-E528. | 4.1 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. <i>American Journal of Hematology</i> , 2014, 89, 1156-1157. | 4.1 | 35 |
| 20 | Hypoxic Response Contributes to Altered Gene Expression and Precapillary Pulmonary Hypertension in Patients With Sickle Cell Disease. <i>Circulation</i> , 2014, 129, 1650-1658. | 1.6 | 32 |
| 21 | Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. <i>Blood Advances</i> , 2020, 4, 1978-1986. | 5.2 | 28 |
| 22 | Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. <i>Blood Advances</i> , 2020, 4, 1501-1511. | 5.2 | 28 |
| 23 | The nephropathy of sickle cell trait and sickle cell disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 361-377. | 9.6 | 26 |
| 24 | Comparison of Patients from Nigeria and the USA Highlights Modifiable Risk Factors for Sickle Cell Anemia Complications. <i>Hemoglobin</i> , 2014, 38, 236-243. | 0.8 | 24 |
| 25 | Patterns of opioid use in sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 1102-1106. | 4.1 | 24 |
| 26 | Association of circulating transcriptomic profiles with mortality in sickle cell disease. <i>Blood</i> , 2017, 129, 3009-3016. | 1.4 | 22 |
| 27 | Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. <i>Kidney International</i> , 2021, 100, 1292-1302. | 5.2 | 22 |
| 28 | Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. <i>Human Genetics</i> , 2015, 134, 895-904. | 3.8 | 20 |
| 29 | Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods. <i>Transfusion</i> , 2018, 58, 1588-1596. | 1.6 | 20 |
| 30 | HMOX1 and acute kidney injury in sickle cell anemia. <i>Blood</i> , 2018, 132, 1621-1625. | 1.4 | 20 |
| 31 | Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vasoocclusive Pain Crises in Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2020, 40, 535-543. | 2.6 | 19 |
| 32 | Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. <i>Pharmacotherapy</i> , 2020, 40, 525-534. | 2.6 | 17 |
| 33 | Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy.. <i>Blood</i> , 2009, 114, 2077-2077. | 1.4 | 17 |
| 34 | Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis. <i>American Journal of Hematology</i> , 2018, 93, E45-E47. | 4.1 | 16 |
| 35 | Risk factors for vitamin D deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2018, 181, 828-835. | 2.5 | 16 |
| 36 | Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. <i>British Journal of Haematology</i> , 2018, 182, 259-270. | 2.5 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models. <i>Translational Research</i> , 2018, 197, 1-11. | 5.0 | 15 |
| 38 | Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. <i>American Journal of Hematology</i> , 2018, 93, E107-E109. | 4.1 | 15 |
| 39 | Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers. <i>Transfusion</i> , 2015, 55, 864-874. | 1.6 | 14 |
| 40 | Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 350-357. | 0.4 | 14 |
| 41 | Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, E376-E380. | 4.1 | 14 |
| 42 | Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. <i>British Journal of Haematology</i> , 2019, 185, 116-127. | 2.5 | 14 |
| 43 | Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. <i>PLoS ONE</i> , 2020, 15, e0229710. | 2.5 | 14 |
| 44 | Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. <i>JMIR Research Protocols</i> , 2021, 10, e29014. | 1.0 | 14 |
| 45 | Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy. <i>American Journal of Nephrology</i> , 2015, 41, 487-493. | 3.1 | 12 |
| 46 | Associations of α -thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. <i>Blood Advances</i> , 2017, 1, 693-698. | 5.2 | 12 |
| 47 | Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1565. | 2.4 | 12 |
| 48 | FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. <i>Blood</i> , 2020, 136, 19-20. | 1.4 | 12 |
| 49 | Role of Ethnicity in Clinical Outcomes of Patients with Ph-Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2012, 120, 2076-2076. | 1.4 | 12 |
| 50 | Use of anti-inflammatory analgesics in sickle-cell disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 656-660. | 1.5 | 11 |
| 51 | Fixed low-dose hydroxyurea for the treatment of adults with sickle cell anemia in Nigeria. <i>American Journal of Hematology</i> , 2018, 93, E193. | 4.1 | 11 |
| 52 | The morbidity and mortality of end stage renal disease in sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E138-E141. | 4.1 | 11 |
| 53 | Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. <i>Haematologica</i> , 2021, 106, 1749-1753. | 3.5 | 11 |
| 54 | Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. <i>Pharmacotherapy</i> , 2016, 36, 1166-1172. | 2.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation. <i>Western Journal of Nursing Research</i> , 2019, 41, 555-575. | 1.4 | 10 |
| 56 | Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , 2020, 1, 623-630. | 2.1 | 10 |
| 57 | A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia. <i>Blood</i> , 2016, 128, 265-265. | 1.4 | 10 |
| 58 | Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2011, 153, 386-392. | 2.5 | 9 |
| 59 | A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 300-306. | 2.4 | 9 |
| 60 | Erythropoiesis-stimulating agents in sickle cell anaemia. <i>British Journal of Haematology</i> , 2018, 182, 602-605. | 2.5 | 9 |
| 61 | Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 947-948. | 1.0 | 8 |
| 62 | Trans-ethnic genome-wide association study of blood metabolites in the Chronic Renal Insufficiency Cohort (CRIC) study. <i>Kidney International</i> , 2022, 101, 814-823. | 5.2 | 8 |
| 63 | Program expansion of a day hospital dedicated to manage sickle cell pain. <i>American Journal of Hematology</i> , 2018, 93, E20-E21. | 4.1 | 7 |
| 64 | Maximum tolerated dose vs fixed low-dose hydroxyurea for treatment of adults with sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, E112-E115. | 4.1 | 7 |
| 65 | ARTS: automated randomization of multiple traits for study design. <i>Bioinformatics</i> , 2014, 30, 1637-1639. | 4.1 | 6 |
| 66 | Conjunctival microvascular hemodynamics following vaso-occlusive crisis in sickle cell disease. <i>Clinical Hemorheology and Microcirculation</i> , 2016, 62, 359-367. | 1.7 | 6 |
| 67 | The experience of adults with sickle cell disease and their HLA-matched adult sibling donors after allogeneic hematopoietic stem cell transplantation. <i>Journal of Advanced Nursing</i> , 2019, 75, 2943-2951. | 3.3 | 6 |
| 68 | Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. <i>British Journal of Haematology</i> , 2021, 194, 767-778. | 2.5 | 6 |
| 69 | Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. <i>Blood</i> , 2019, 134, 616-616. | 1.4 | 6 |
| 70 | Use of metformin in patients with sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E13-E15. | 4.1 | 5 |
| 71 | Voxelotor and albuminuria in adults with sickle cell anaemia. <i>British Journal of Haematology</i> , 2022, . . | 2.5 | 5 |
| 72 | Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. <i>Blood Advances</i> , 2022, 6, 4461-4470. | 5.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. <i>Human Molecular Genetics</i> , 2016, 25, ddw299. | 2.9 | 4 |
| 74 | Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. <i>Haematologica</i> , 2017, 102, e282-e284. | 3.5 | 4 |
| 75 | Kidney ultrasound findings according to kidney function in sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, E288-E291. | 4.1 | 4 |
| 76 | Engulfment and cell motility 1 (ELMO1) and apolipoprotein A1 (APOA1) as candidate genes for sickle cell nephropathy. <i>British Journal of Haematology</i> , 2021, 193, 628-632. | 2.5 | 4 |
| 77 | Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease. <i>American Journal of Nephrology</i> , 2021, 52, 582-587. | 3.1 | 4 |
| 78 | Urinary Ceruloplasmin Concentration Predicts Development of Kidney Disease in Sickle Cell Disease Patients. <i>Blood</i> , 2016, 128, 4865-4865. | 1.4 | 4 |
| 79 | Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. <i>British Journal of Haematology</i> , 2020, 191, e70-e72. | 2.5 | 3 |
| 80 | Heme A1M TM at the kidney in sickle cell disease. <i>Blood</i> , 2020, 135, 979-981. | 1.4 | 3 |
| 81 | Association of Blood Pressure Genetic Risk Score with Cardiovascular Disease and CKD Progression: Findings from the CRIC Study. <i>Kidney360</i> , 2021, 2, 1251-1260. | 2.1 | 3 |
| 82 | Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience. <i>Journal of Clinical Apheresis</i> , 2021, 36, 634-644. | 1.3 | 3 |
| 83 | Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. <i>Blood</i> , 2015, 126, 3400-3400. | 1.4 | 3 |
| 84 | Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. <i>Blood</i> , 2017, 130, 981-981. | 1.4 | 3 |
| 85 | Clinical, Laboratory, and Genetic Risk Factors for Thrombosis in Sickle Cell Disease. <i>Blood</i> , 2018, 132, 9-9. | 1.4 | 3 |
| 86 | Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. <i>Haematologica</i> , 2021, 106, 1745-1748. | 3.5 | 3 |
| 87 | The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial. <i>Blood</i> , 2020, 136, 32-33. | 1.4 | 3 |
| 88 | Hyperkalemia and Metabolic Acidosis Occur at Higher Estimated Glomerular Filtration Rates in Sickle Cell Disease. <i>Kidney360</i> , 0, , 10.34067/KID.0006802021. | 2.1 | 3 |
| 89 | Potential Contribution of Pulmonary Thromboembolic Disease in Pulmonary Hypertension in Sickle Cell Disease. <i>Annals of the American Thoracic Society</i> , 2020, 17, 899-901. | 3.2 | 2 |
| 90 | Effects of renin-angiotensin blockade and APOL1 on kidney function in sickle cell disease. <i>EJHaem</i> , 2021, 2, 483-484. | 1.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts. <i>Blood</i> , 2018, 132, 4817-4817. | 1.4 | 2 |
| 92 | Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia. <i>Blood</i> , 2019, 134, 3558-3558. | 1.4 | 2 |
| 93 | Phase 1 Evaluation of Oral Tetrahyrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. <i>Blood</i> , 2016, 128, 124-124. | 1.4 | 2 |
| 94 | Hydroxyurea for Treatment of Sickle Cell Disease in Adults in Africa. <i>Blood</i> , 2016, 128, 1305-1305. | 1.4 | 2 |
| 95 | Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia. <i>Blood</i> , 2019, 134, 2268-2268. | 1.4 | 2 |
| 96 | Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb S α thalassemia sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, E316-7. | 4.1 | 1 |
| 97 | Reply to <sc>R</sc>uan <sc>X</sc> et al: âœA comment on pattern of opioid use in sickle cell diseaseâœ. <i>American Journal of Hematology</i> , 2017, 92, E43. | 4.1 | 1 |
| 98 | High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E5-E7. | 4.1 | 1 |
| 99 | <i>S100B</i> has pleiotropic effects on vasoâœocclusive manifestations in sickle cell disease. <i>American Journal of Hematology</i> , 2020, 95, E62-E65. | 4.1 | 1 |
| 100 | Using machine learning to predict rapid decline of kidney function in sickle cell anemia. <i>EJHaem</i> , 2021, 2, 257-260. | 1.0 | 1 |
| 101 | The vasculopathic cord between preâœclampsia and kidney function in sickle cell disease. <i>British Journal of Haematology</i> , 2021, 194, 947-949. | 2.5 | 1 |
| 102 | Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients. <i>Blood</i> , 2018, 132, 313-313. | 1.4 | 1 |
| 103 | Regulatory Genetic Variation at the S100B Gene Associates with Vaso-Occlusive Manifestations in Sickle Cell Disease. <i>Blood</i> , 2018, 132, 1063-1063. | 1.4 | 1 |
| 104 | Assessment of Bone Marrow Function in Sickle Cell Anaemia Patients Using Corrected Reticulocyte Counts. <i>Blood</i> , 2015, 126, 4581-4581. | 1.4 | 1 |
| 105 | Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Kidney Function in Patients with Sickle Cell Disease. <i>Blood</i> , 2016, 128, 3666-3666. | 1.4 | 1 |
| 106 | Genetic Modifiers Identify a High Risk Group for Stroke in Three Independent Cohorts of Sickle Cell Anemia Patients. <i>Blood</i> , 2016, 128, 1015-1015. | 1.4 | 1 |
| 107 | Biomarkers of Cardiopulmonary, Renal, and Liver Dysfunction in an Adult Sickle Cell Disease Cohort. <i>Blood</i> , 2019, 134, 3574-3574. | 1.4 | 1 |
| 108 | Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. <i>Blood</i> , 2021, 138, 2051-2051. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Use of Multiple Urinary Biomarkers for Early Detection of Chronic Kidney Disease in Sickle Cell Anemia Patients. <i>Blood</i> , 2020, 136, 30-30. | 1.4 | 1 |
| 110 | Black and White Adults With CKD Hospitalized With Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2022, , . | 1.9 | 1 |
| 111 | Thrombomodulin and <scp>multiorgan</scp> failure in sickle cell anemia. <i>American Journal of Hematology</i> , 2022, 97, . | 4.1 | 1 |
| 112 | Improvement of Hemolytic Anemia with GBT1118 is Reno-protective in Transgenic Sickle Mice. <i>Blood Advances</i> , 0, , . | 5.2 | 1 |
| 113 | Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner <i>etÂal</i>. <i>British Journal of Haematology</i> , 2019, 186, 782-783. | 2.5 | 0 |
| 114 | Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. <i>Obesity Surgery</i> , 2019, 29, 3762-3764. | 2.1 | 0 |
| 115 | Evaluation of pointâ€ofâ€care International Normalized Ratio in sickle cell disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12533. | 2.3 | 0 |
| 116 | African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 3131-3131. | 1.4 | 0 |
| 117 | Significance of, and Difficulty in Diagnosing, Erythropoietin Deficiency in Sickle Cell Anemia. <i>Blood</i> , 2008, 112, 2479-2479. | 1.4 | 0 |
| 118 | Favorable Responses to Novel Agents for Multiple Myeloma in African American Patients,. <i>Blood</i> , 2011, 118, 4213-4213. | 1.4 | 0 |
| 119 | Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd. <i>Blood</i> , 2012, 120, 4491-4491. | 1.4 | 0 |
| 120 | Clinical and Laboratory Predictors for Renal Damage in Sickle Cell Disease. <i>Blood</i> , 2012, 120, 3252-3252. | 1.4 | 0 |
| 121 | Hemoglobinuria Is a Risk Factor For Kidney Disease Progression In Sickle Cell Anemia. <i>Blood</i> , 2013, 122, 996-996. | 1.4 | 0 |
| 122 | Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intensity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. <i>Blood</i> , 2013, 122, 3285-3285. | 1.4 | 0 |
| 123 | LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk hematologic malignancies: A phase I study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7045-7045. | 1.6 | 0 |
| 124 | Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or SBeta+ -Thalassemia Sickle Cell Disease. <i>Blood</i> , 2015, 126, 3413-3413. | 1.4 | 0 |
| 125 | CCN2 - Exploring a New Biomarker in Myelofibrosis. <i>Blood</i> , 2015, 126, 4063-4063. | 1.4 | 0 |
| 126 | Allogeneic Hematopoietic Cell Transplant in Sickle Cell Disease. , 2016, , 89-96. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Elevated Levels of Hgfl Protein in Sickle Cell Disease Urine Samples That Induce Glomerular Permeability. Blood, 2016, 128, 4841-4841. | 1.4 | 0 |
| 128 | Progressive Glomerular Damage in Sickle Cell Trait and Sickle Cell Anemia Mouse Models. Blood, 2016, 128, 3637-3637. | 1.4 | 0 |
| 129 | Quantitative Proteomics Identify Urinary Hgfl Protein As a Potential Marker for the Development of Chronic Kidney Disease in Sickle Cell Disease Patients. Blood, 2017, 130, 967-967. | 1.4 | 0 |
| 130 | Pulmonary Function Abnormalities in Adults with Sickle Cell Anemia. Blood, 2018, 132, 3664-3664. | 1.4 | 0 |
| 131 | Role of Automated Red Cell Exchange in Acute and Chronic Complications of Sickle Cell Disease. Blood, 2018, 132, 3674-3674. | 1.4 | 0 |
| 132 | Cancer Incidence in Sickle Cell Disease:an Institutional Experience. Blood, 2018, 132, 1087-1087. | 1.4 | 0 |
| 133 | Kidney Ultrasound Findings in Sickle Cell Anemia According to Kidney Disease and the APOL1 G1/G2 Risk Variants. Blood, 2018, 132, 3663-3663. | 1.4 | 0 |
| 134 | Association of Inpatient Opioid Utilization and Readmission Risk in Sickle Cell Disease. Blood, 2018, 132, 4699-4699. | 1.4 | 0 |
| 135 | Maximum Tolerated Dose Versus Fixed Low-Dose Hydroxyurea for Treatment of Adults with Sickle Cell Anemia - Retrospective Comparison of Two Studies. Blood, 2018, 132, 3656-3656. | 1.4 | 0 |
| 136 | A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients. Blood, 2018, 132, 5218-5218. | 1.4 | 0 |
| 137 | Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study. Blood, 2019, 134, 1004-1004. | 1.4 | 0 |
| 138 | Risk Factors for Kidney Disease in Hb SC and Hb S ⁺ -Thalassemia Sickle Cell Disease. Blood, 2019, 134, 2299-2299. | 1.4 | 0 |
| 139 | Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. Blood, 2019, 134, 3390-3390. | 1.4 | 0 |
| 140 | The Burden of Atrial Fibrillation in Sickle Cell Disease. Blood, 2021, 138, 3119-3119. | 1.4 | 0 |
| 141 | HIF-Mediated and Non-HIF-Mediated Differential Gene Expressions in Sickle Cell Reticulocyte and Their Impact on Clinical Manifestations. Blood, 2021, 138, 950-950. | 1.4 | 0 |
| 142 | Naloxone Use for Opioid Reversal in Patients with Sickle Cell Disease. Blood, 2021, 138, 2038-2038. | 1.4 | 0 |
| 143 | Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease. Blood, 2020, 136, 24-25. | 1.4 | 0 |
| 144 | Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. Blood, 2020, 136, 21-22. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Mass-Spectrometry Analysis of Urinary Biomarkers of Endothelial Injury in Sickle Cell Anemia Patients. Blood, 2020, 136, 28-29. | 1.4 | 0 |
| 146 | Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. Blood, 2020, 136, 18-19. | 1.4 | 0 |
| 147 | Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. Blood, 2020, 136, 34-35. | 1.4 | 0 |
| 148 | <scp>COVID</scp>â€19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan <scp>US</scp> population. American Journal of Hematology, 2022, 97, . | 4.1 | 0 |
| 149 | Title is missing!. , 2020, 15, e0229710. | | 0 |
| 150 | Title is missing!. , 2020, 15, e0229710. | | 0 |
| 151 | Title is missing!. , 2020, 15, e0229710. | | 0 |
| 152 | Title is missing!. , 2020, 15, e0229710. | | 0 |